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Anxiety is most common among Alzheimer’s disease (AD) patients with an age at onset under age 65. Apolipoprotein E4 (apoE4)
is a risk factor for developing AD at an earlier age and might contribute to this eﬀect. In mice, apoE plays a role in the regulation of
anxiety, which might involve histamine receptor-mediated signaling and steroidogenesis in the adrenal gland. In addition, human
apoE isoforms have diﬀerential eﬀects on anxiety in adult mice lacking apoE and probable AD patients. Compared to wild-type
mice, mice lacking apoE and apoE4 mice showed pathological alterations in the central nucleus of the amygdala, which is involved
inregulationofanxiety.ApoE4,butnotmicelackingapoE,orapoE3miceshowedimpaireddexamethasonesuppressionofplasma
corticosterone. Understanding how apoE modulates measures of anxiety might help the developments of therapeutic targets to
reduce or even prevent measures of anxiety in health and in dementing illnesses.
Copyright © 2007 Jacob Raber. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Noncognitive behavioral changes are the major cause of in-
stitutionalization of AD patients and a major concern for
their caregivers [1–3]. Such changes are also a negative pre-
dictor of survival and quality of life for AD patients and con-
tribute to increased costs [4, 5]. However, they have received
much less attention than cognitive impairments. Most phar-
macological strategies for controlling behavioral changes, in-
cluding treatment with benzodiazepines, cause deterioration
in mental performance and motor function [6]. In AD, anx-
iety is inversely related to mini-mental state examination
(MMSE) score (i.e., worse with more severe dementia) [7].
Anxiety symptoms occur in about 50% [8] to 75% [9]o fA D
patients. A study describing the relationship between anx-
iety and nighttime behavioral disturbance in a community
dwelling sample of 153 AD patients revealed symptoms of
anxiety and patient awakening associated with higher levels
of patient anxiety and patient impairments in activities of
daily living (ADL) in 56% of the patients [10]. Individual-
patient anxiety symptoms were risk factors for patient awak-
enings [10]. Anxiety symptoms become more common as
the disease progresses and are associated with greater disabil-
ity in daily activities [7, 8]. In more than half of the cases,
the caregivers demand therapeutic intervention regardless of
the eﬀects on cognitive and motor function. Therefore, there
is a need to better understand the mechanisms underlying
increased anxiety and to develop better treatments for these
conditions.
2. APOE, BRAIN FUNCTION, AND AD
ApoEplaysanimportantroleinthemetabolismandredistri-
bution of lipoproteins and cholesterol [11]. The three major
human apoE isoforms are encoded by distinct alleles (ε2, ε3,
and ε4). Compared with ε2a n dε3, ε4 increases the risk of
cognitive impairments and of developing AD [12]. This in-
creased risk might involve a loss of trophic function of apoE4
or gain of toxic function of apoE4. Anxiety is most common
among AD patients with a younger age at onset (under age
65) [7]. ApoE4 is a risk factor for developing AD at an earlier
age [12] and might contribute to this eﬀect.
3. ROLE OF APOE IN REGULATING MEASURES OF
ANXIETY REVEALED IN APOE–/–MICE
The elevated plus maze can be used to assess measures of
anxiety in mice (Figure 1). The plus maze consists of a per-
pendicular cross elevated above the ﬂoor. The sides of one
axis are walled oﬀ. There are infrared photobeams to record
movements. Mice will prefer the safety of the enclosed,2 Neural Plasticity
Figure 1: Elevated plus maze: the mice are tested for 10 minutes;
while they are curious to explore the open areas, they are anxious to
do so.
darker arms, but they like to explore the open arms and poke
over the edge. Less anxious mice will venture more onto the
open arms, and poke their heads more over the edges of the
open arms. Male Apoe−/− (C57BL/6J-Apoetm1Unc) and wild-
type C57BL/6J mice were obtained from the Jackson Labora-
tory (Bar Harbor, Me). When measures of anxiety in the ele-
vated plus maze were assessed in 6-month-old Apoe−/− male
and wild-type control mice, Apoe−/− mice showed increased
measures of anxiety [13]. These changes are age-dependent
and not seen in 3-month-old mice.
4. APOE AND ADRENAL STEROIDOGENESIS
Liver and brain are the major sites of apoE synthesis. How-
ever, many other tissues, particularly steroidogenic tissues
suchastheadrenalgland,alsoexpressapoE[14,15].Adrenal
apoE expression is the highest in cortical cells that synthe-
size glucocorticoids (GCs), declines when steroidogenesis is
stimulated, and increases when it is blocked [14, 15]. The
function of apoE synthesized by the adrenal gland is unclear.
Apoe−/− mice show an age-dependent dysregulation of the
hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis
regulatesthesecretionofGCsthroughamechanismthatpri-
marily aﬀects the adrenal gland. In Apoe−/− mice, activation
oftheHPAaxisisseenatthesametimeasincreasedmeasures
of anxiety are observed in the elevated plus maze. Apoe−/−
mice have an age-dependent increase in basal adrenal cor-
ticosterone content and abnormally increased plasma corti-
costerone after restraint stress and anxiety testing in the el-
evated plus maze [13]. Apoe−/− mice also show increases in
lipid droplets in adrenal cortex and medulla [13]. These data
are consistent with hypersecretion of adrenal corticosterone
andincreasedadrenalcorticosteronecontentandwiththere-
portedinverserelationshipbetweenthelevelsofapoEmRNA
and adrenal steroidogenesis, and they suggest a key role for
apoE in the tonic inhibition of steroidogenesis and adrenal
cortical activity.
5. HISTAMINE AND ANXIETY OF APOE–/–MICE
Histamine increases measures of anxiety [16], and altered
histamine signaling could contribute to increased measures
of anxiety in adult Apoe−/− male mice. We began to as-
sess the possible role of histamine receptor-mediated signal-
ing in regulating measures of anxiety in Apoe−/− and wild-
type mice. Drugs were dissolved in saline and administered
by intraperitoneal injection 1 hour before behavioral testing
at the indicated doses, selected based on preliminary stud-
ies. The person testing the mice was blinded to genotype
and treatment. The histamine H3 r e c e p t o r sm o d u l a t eh i s -
tamine release and synthesis via negative feedback. We as-
sessed whether young (3–5-month old) Apoe−/−mice,w h i c h
show similar measures of anxiety in the anxiety-provoking
open arms of the plus maze, respond diﬀerentially to his-
tamine H3 receptor ligands. Anxiety levels were assessed
1hour after intraperitoneal administration of thioperamide
(5mg/kg) or saline. Wild-type mice treated with H3 recep-
tor antagonist thioperamide showed increased measures of
anxiety as compared to wild-type mice treated with saline
[17]. The total activity in the closed arms was comparable in
the saline- and thioperamide-treated wild-type mice. These
data indicate that the diﬀerences in measures in the open
arms were not caused by diﬀerences in activity levels. In con-
trast, thioperamide had no eﬀect on measures of anxiety in
Apoe−/− mice.
Next we determined whether in wild-type and Apoe−/−
mice, H3 antagonists also have diﬀerential eﬀects on novel
objectrecognition[18,19].Duringthetrainingsession,mice
wereallowedtoexplorefor15minutesanopenﬁeldcontain-
ing two objects. For the retention session (24 hours later),
they were placed back into the same open ﬁeld for 15 min-
utes, after one of the familiar objects had been replaced with
a novel object and the other familiar object with an exact
replica. The percentage of time the mice spent exploring the
novelversusthefamiliarobjectrelativetothetotalamountof
time they explored either object in the retention session was
used as a measure of object recognition memory. Wild-type
and Apoe−/− mice received saline, thioperamide (5mg/kg),
or clobenpropit (10mg/kg) during the training and reten-
tion sessions [17]. The recently cloned H4 receptor [20]w a s
found to have an aﬃnity for H3-speciﬁc ligands. To rule out
the possible contribution of the H4 receptor to the eﬀects of
thioperamide, we also treated wild-type and Apoe−/− mice
withclobenpropit,aH3-speciﬁcantagonistthatwasreported
to be an H4 r e c e p t o ra g o n i s ta sw e l l[ 20]. In the training ses-
sion, all groups of mice spent a comparable amount of time
exploring each object. In the retention session, the saline-
treated wild-type and Apoe−/− mice spent signiﬁcantly more
time exploring the novel object (wild-type: 8.37 ± 0.93 sec-
onds; Apoe−/−:9 .34 ± 2.76seconds) than the familiar object
(wild-type:5.43±0.69seconds;Apoe−/−:5.15±1.25seconds),
whereas the thioperamide- and clobenpropit-treated wild-
type and Apoe−/− mice spent equal amounts of time explor-
ing both objects. The similar eﬀects of thioperamide and
clobenpropit on novel object recognition indicate that they
are mediated by the H3 receptor and not the H4 receptor.Jacob Raber 3
To determine whether H3 ligands have diﬀerential ef-
fects on emotional learning and memory in wild-type and
Apoe−/− mice, passive avoidance learning was used. Mice
wereplaced in alighted compartmentof achamber also con-
tainingadarkcompartment.Theyenteredthedarkcompart-
mentbypreferencewheretheyreceivedabriefandslightfoot
shock (0.3mA for 1second). After 24hours, the mice were
again placed in the light compartment, and the time to reen-
terthedarkcompartmentwasmeasured.Drugswereadmin-
istered 1hour before behavioral testing on both days. Both
saline- and thioperamide- (5mg/kg) treated wild-type and
Apoe−/− miceshowedemotionallearningandmemoryasthe
time to reenter the dark chamber was signiﬁcantly higher
on day 2 than day 1. There was no eﬀect of thioperamide
but consistent with increased measures of anxiety of Apoe−/−
mice in the elevated plus maze, the latency to enter the dark
c o m p a r t m e n to nd a y1w a sl o w e ri nApoe−/− than wild-type
mice (P<. 05, Tukey-Kramer).
To determine whether there are diﬀerences in H3 recep-
tor expression in young Apoe−/− and wild-type mice (3–5-
monthold)whichcouldhavecontributedtotheirdiﬀerential
response to H3 antagonists on measures of anxiety, we per-
formed saturation analysis with [3H]-Nα-methylhistamine
(NAMH) in brain regions that have been implicated in cog-
nition or emotion [17]. The total number of receptors (Bmax
innM)intheamygdala(wild-type:87.3±2.5;Apoe−/−:81.8±
2.3), cortex (wild-type: 119.9±3.0; Apoe−/−:5 6 .8±5.8), and
hippocampus (wild-type: 108.4 ± 10.5; Apoe−/−:2 9 .1 ± 1.7)
waslowerinApoe−/− thaninwild-typemice.Inthehypotha-
lamus, Bmax was not diﬀerent between the groups. There was
no diﬀerence in the binding aﬃnities of [3H]-NAMH in any
brain region. Thus, there is no simple association between
levels of H3 receptor expression in structures associated with
anxiety versus cognition, which could explain why H3 antag-
onists impaired hippocampus- and cortex-dependent novel
object recognition [18] but did not increase more amygdala-
dependent measures of anxiety in the plus maze.
In experimental models of anxiety, stimulation of H1−,
but not of H2−, receptors increases measures of anxiety
[16, 21, 22]. In Apoe−/− mice, reduced negative feedback via
H3 receptors could increase histamine release and signaling
of H1 and H2 receptors. To determine whether in Apoe−/−
mice increased signaling of these receptors contributed to
the increased measures of anxiety, 3–5-month-old wild-type
and Apoe−/− mice were assessed in the elevated plus maze
1hour after intraperitoneal administration of the H1 antago-
nist mepyramine (5.6mg/kg), the H2 antagonist zolantidine
(10mg/kg), or saline. Apoe−/− mice treated with mepyra-
mine, but not with zolantidine, showed reduced measures of
anxietyascomparedtoApoe−/− micetreatedwithsaline[17].
The total activity in the closed arms was comparable and not
signiﬁcantlydiﬀerentbetweenthesaline-,mepyramine-,and
zolantidine-treated Apoe−/− mice, indicating that the diﬀer-
ences in measures in the open arms were not caused by dif-
ferences in activity levels. In contrast, mepyramine had no
eﬀect on measures of anxiety in wild-type mice. The lack of
an eﬀect of H1 receptor blockade on measures of anxiety in
wild-type C57Bl/6J mice is consistent with the lack of eﬀect
Figure 2: Passive avoidance: the mice are trained to avoid the pre-
ferred dark compartment by paring it with an aversive stimulus.
of H1 receptor blockade on measures of anxiety in wild-type
ddY mice and it supports that the H1 receptor becomes acti-
vated at higher levels of histamine release [21]. The reduced
measures of anxiety in Apoe−/− mice after H1 receptor block-
ade are consistent with the reported antagonizing eﬀects of
mepyramine on experimental anxiety induced by histamine
releasers [16, 21] and the anxiogenic eﬀects of the H1 recep-
tor agonist and H3 receptor antagonist betahistine [22].
In Apoe−/− mice, the eﬀects of mepyramine on mea-
sures of anxiety in the plus maze were not associated with
a reduced HPA axis response. Plasma ACTH and corticos-
terone levels were assessed directly after plus-maze testing
[23]. Compared to saline controls, mepyramine reduced
the plasma corticosterone levels in wild-type (saline: 179 ±
38ng/mL, n = 6; mepyramine: 89±26ng/mL, n = 6; P<. 05
Tukey-Kramer), but not in Apoe−/− (saline: 206 ± 30ng/mL,
n = 8;mepyramine:224±10ng/mL,n = 9)mice.Therewere
an eﬀect of genotype (P<. 01) and a genotype x treatment
interaction (P = .0474). Mepyramine also reduced plasma
ACTH levels in wild-type mice (saline: 121 ± 20pg/mL, n =
6;mepyramine:77±9pg/mL,n = 6;P<. 05Tukey-Kramer),
butnotinApoe−/− mice(saline:57±5pg/mL,n = 8;mepyra-
mine:62±11pg/mL,n = 9).ThesedatashowthatinApoe−/−
mice, mepyramine does not reduce measures of anxiety by
inhibiting the HPA axis response. The dissociation of the ef-
fects of H1 receptor blockade on anxiety from those on the
HPA axis in Apoe−/− and wild-type mice and the diﬀerential
eﬀects of H3 receptor blockade on novel object recognition
and anxiety in Apoe−/−, but not wild-type, mice suggest that
diﬀerential pharmacokinetic proﬁles of histaminergic drugs
in the two genotypes do not underlie the behavioral results.
There are no diﬀerences in H1 receptor expression in
young (3–5-month old) Apoe−/− and wild-type mice. Satu-
ration analysis with [3H] mepyramine in brain regions im-
plicated in cognition or emotion [17] showed similar total
number of receptors (Bmax in nM) in the amygdala (wild-
type: 103.4 ± 13.16; Apoe−/−: 120.9 ± 20.92), cortex (wild-
type: 126.5 ± 8.472; Apoe−/−: 170.0 ± 13.02), hippocampus
(wild-type: 104.0 ± 10.13; Apoe−/−:9 8 .66 ± 11.03), and4 Neural Plasticity
Table 1: Elevated plus-maze performance of 6–8-month-old NSE-apoE mice.
Genotype Distance moved in
closed arms (inches)
Time in closed
arms (s)
R a t i ot i m ei no p e na r m s / t i m e
in open + time in closed arms1
Wild type (n = 8) 1003 ±76 4962 ±85 0.078 ±0.015∗
Apoe−/− (n = 37) 824 ±30 5069 ±113 0.035 ±0.010
apoE3 (n = 27) 917 ±40 4697 ±100 0.087 ±0.013∗∗
apoE4 (n = 17) 886 ±68 5204 ±190 0.022 ±0.007
apoE3/E4 (n = 9) 825 ±66 4807 ±77 0.053 ±0.008
1There was a signiﬁcance of genotype on ratio time in open arms/time in open + time in closed arms (P = .0094).
∗P<. 05, wild-type versus Apoe−/−, apoE4, or apoE3/E4.
∗∗P<. 05 versus Apoe−/− and apoE3/E4, and P<. 01 versus apoE4.
Table 2: Elevated plus-maze performance in 6-month-old GFAP-apoE male mice.
Genotype (line) Distance moved in
closed arms (inches)
Time in closed
arms (s)
R a t i ot i m ei no p e na r m s / t i m e
in open + time in closed arms
Apoe−/− (n = 34) 1050 ±43 475 ±12 0.058 ±0.012
apoE3 (127) (n = 11) 1137 ±59 417 ±14 0.174 ±0.022∗
apoE4 (129) (n = 4) 1194 ±69 479 ±34 0.044 ±0.024
apoE4 (130) (n = 9) 1039 ±36 475 ±24 0.042 ±0.016
∗P<. 05 versus Apoe−/− mice and P<. 01 versus apoE4 (129) and apoE4 (130).
hypothalamus (wild-type: 218.7 ± 22.33; Apoe−/−: 159.4 ±
29.00) of Apoe−/− and wild-type mice and similar binding
aﬃnities of [3H]-mepyramine in each brain region.
6. HUMAN APOE ISOFORMS AND MEASURES
OF ANXIETY
We hypothesized that human apoE isoforms have diﬀeren-
tial eﬀects on measures of anxiety in adult (6–8 months of
age)Apoe−/− miceexpressinghumanapoE3orapoE4atsim-
ilar levels. Apoe−/− male mice without human apoE expres-
sion and apoE4 mice showed increased measures of anxiety
in the elevated plus maze, whereas apoE3 male mice behaved
like wild-type controls (Table 1). These diﬀerential eﬀects of
apoE isoforms on anxiety were age-dependent and not seen
in young (2–4-month-old) male mice.
The isoform-speciﬁc eﬀects of apoE are independent of
the cellular source of apoE. When anxiety levels in the ele-
vated plus maze were assessed in a cohort of 6-month-old
GFAP-apoE male mice, in which the expression of apoE3 or
apoE4 is targeted to astrocytes, GFAP-apoE3, but not GFAP-
apoE4, male mice showed less measures of anxiety in the ele-
vated plus maze than Apoe−/− mice (Table 2). Similar results
wereseenintheelevatedzeromaze,inwhichthemousedoes
not need to turn around in the open areas in order to return
to the closed areas [24].
T h ee l e v a t e dp l u sm a z ei sd i ﬀerent from tests that in-
volve unavoidable anxiety-provoking stimuli, such as acous-
tic stimuli. By assessing the acoustic startle response, we de-
termined that apoE also has age- and isoform-speciﬁc ef-
fects on anxiety elicited by unavoidable acoustic stimuli. To
measure startle reﬂex, we used the SM100 startle monitor
system (Hamilton-Kinder) (Figure 3). At 3 months of age,
there were no eﬀects of apoE isoforms on the acoustic star-
tle response. However, there were diﬀerential eﬀects of apoE
isoforms on the acoustic startle response at 6 months of
age. Apoe−/− mice showed a higher acoustic startle response
than age-matched wild-type mice. This was not present in
apoE3 mice and was present to a lesser extent in apoE4 mice.
There was a diﬀerence in acoustic startle response between
apoE3 and apoE4 mice and between Apoe−/− and apoE3 or
apoE4 mice [25]. Thus, the diﬀerential eﬀects of apoE iso-
forms on measures of anxiety are not limited to avoidable
anxiety-provokingstimuli.Therewerenodiﬀerencesinhear-
ing threshold or fear-potentiated startle in the 6-month-old
male groups.
7. DEXAMETHASONE SUPPRESSION AND APOE4
Impaired suppression of cortisol levels after administration
of dexamethasone is reported in AD [26]. Therefore, we ex-
amined whether dexamethasone could suppress plasma cor-
ticosterone in adult apoE transgenic mice [25]. Mice were
injected with dexamethasone (0.1mg/kg) or saline between
9:00a.m. and 10:00a.m., and trunk blood was collected
6hourslater[27]. Compared to saline, dexamethasone sup-
pressed plasma corticosterone levels in wild-type, Apoe−/−,
and apoE3 mice but dexamethasone suppression was im-
paired in apoE4 mice. The impaired dexamethasone sup-
pression in the apoE4 mice might relate to other perturba-
tions of cortisol responsivity observed in AD, including re-
duced cortisol-mediated regulation of hippocampal glucose
metabolism [28] and dexamethasone sensitivity of periph-
eral blood nuclear cells [29].Jacob Raber 5
Figure 3:Acousticstartle:themiceareplacedonasensingplatform
and their response to acoustic stimuli is recorded.
8. THE AMYGDALA AND APOE4
The diﬀerential eﬀects of apoE on measures of anxiety were
associated with neuropathological alterations in the central
nucleus of the amygdala, which plays an important role
in the regulation of anxiety. Compared to wild-type mice,
Apoe−/− and apoE4, but not apoE3, mice had lower levels of
microtubule-associated protein (MAP) 2-positive neuronal
dendrites (P<. 05). These changes were age-dependent.
Three-month-old wild-type and Apoe−/− mice had similar
levels of MAP 2-positive neuronal dendrites. Interestingly, in
nondemented human subjects [30] and in AD subjects [31],
amygdala atrophy increased with increasing ε4a l l e l ed o s e .
However, other studies did not ﬁnd eﬀects of the ε4a l l e l e
on amygdala atrophy. This might relate to diﬀerences in the
mean age of the subjects in the diﬀerent studies and a de-
crease in the eﬀect of ε4w i t ha d v a n c e da g e .
9. DIFFERENTIAL EFFECTS OF APOE ISOFORMS ON
MEASURES OF ANXIETY IN PRAD PATIENTS
Consistent with the mouse studies, apoE also has isoform-
dependent eﬀects on measures of anxiety in probable AD
(PRAD) patients [25]. Diagnosis of probable AD was made
in each case according to NINDS-ADRDA criteria [32]. Cor-
nell depression scale and neuropsychiatric inventory (NPI)
were recorded for all subjects (mean age ± SEM; all subjects:
73±1years;ε3/ε3:75±3years;ε3/ε4:73±2years;ε4/ε4:71±2
years). Subjects were nonsmokers in good general health and
free of past or present major psychiatric or neurological dis-
orders (other than AD). Male ε4/ε4s u b j e c t sh a dh i g h e ra n x -
iety scores than gender-matched ε3/ε3s u b j e c t s( P<. 05). In
males, but not in females, subjects with ε4/ε4 had also higher
anxiety scores than those with ε3/ε4, suggesting that apoE3
canantagonize the eﬀectsof apoE4onmeasuresofanxiety in
malesbutnotinfemales.Theanxiety scoresdid notcorrelate
with the mini-mental state exam (MMSE) scores. Compared
to ε3/ε3 male subjects, sleep disturbances were lower in ε4/ε4
(P<. 01) and ε3/ε4( P<. 05) male subjects. Thus, sleep dis-
turbances did not correlate or contribute to anxiety scores.
ApoE did not have isoform-dependent eﬀects on apathy or
depression scores.
10. CONCLUSIONS
ApoE isoforms have diﬀerential eﬀects on measures of anx-
iety in Apoe−/− mice expressing human apoE3 or apoE4 at
similar levels and in PRAD subjects. The ε4a l l e l ei sa l s oa s -
sociated with depression in some [33–35] but not other [36–
40] studies. As noncognitive behavioral changes are the ma-
jor cause of institutionalization of AD patients and a major
concernfortheircaregivers,moreresearchaimingatincreas-
ing our understanding of mechanisms underlying these be-
havioral changes is needed to advance treatment strategies to
reduce these changes.
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